Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Brain-specific repression of AMPKα1 alleviates pathophysiology in Alzheimer’s model mice
Helena R. Zimmermann, … , C. Dirk Keene, Tao Ma
Helena R. Zimmermann, … , C. Dirk Keene, Tao Ma
Published March 26, 2020
Citation Information: J Clin Invest. 2020;130(7):3511-3527. https://doi.org/10.1172/JCI133982.
View: Text | PDF
Research Article Aging Neuroscience

Brain-specific repression of AMPKα1 alleviates pathophysiology in Alzheimer’s model mice

  • Text
  • PDF
Abstract

AMPK is a key regulator at the molecular level for maintaining energy metabolism homeostasis. Mammalian AMPK is a heterotrimeric complex, and its catalytic α subunit exists in 2 isoforms: AMPKα1 and AMPKα2. Recent studies suggest a role of AMPKα overactivation in Alzheimer’s disease–associated (AD-associated) synaptic failure. However, whether AD-associated dementia can be improved by targeting AMPK remains unclear, and roles of AMPKα isoforms in AD pathophysiology are not understood. Here, we showed distinct disruption of hippocampal AMPKα isoform expression patterns in postmortem human AD patients and AD model mice. We further investigated the effects of brain- and isoform-specific AMPKα repression on AD pathophysiology. We found that repression of AMPKα1 alleviated cognitive deficits and synaptic failure displayed in 2 separate lines of AD model mice. In contrast, AMPKα2 suppression did not alter AD pathophysiology. Using unbiased mass spectrometry–based proteomics analysis, we identified distinct patterns of protein expression associated with specific AMPKα isoform suppression in AD model mice. Further, AD-associated hyperphosphorylation of eukaryotic elongation factor 2 (eEF2) was blunted with selective AMPKα1 inhibition. Our findings reveal isoform-specific roles of AMPKα in AD pathophysiology, thus providing insights into potential therapeutic strategies for AD and related dementia syndromes.

Authors

Helena R. Zimmermann, Wenzhong Yang, Nicole P. Kasica, Xueyan Zhou, Xin Wang, Brenna C. Beckelman, Jingyun Lee, Cristina M. Furdui, C. Dirk Keene, Tao Ma

×

Figure 3

Suppression of AMPKα does not alter AD-associated brain Aβ pathology or tau phosphorylation.

Options: View larger image (or click on image) Download as PowerPoint
Suppression of AMPKα does not alter AD-associated brain Aβ pathology or ...
(A) Representative images of cortical Aβ plaque deposition in WT, Tg, α1/Tg, and α2/Tg mice. Scale bars: 100 μm (×20 images); 50 μm (×60 images). (B) Percentage of cortex covered by Aβ plaques in Tg, α1/Tg, and α2/Tg mice. n = 9 slices/3 mice. (C) Representative images of hippocampal Aβ plaque deposition in WT, Tg, α1/Tg, and α2/Tg mice. Scale bars: 100 μm (×20 images); 50 μm (×60 images). (D) Percentage of hippocampal area covered by amyloid plaques in Tg, α1/Tg, and α2/Tg mice. n = 9 slices/3 mice. (E) ELISA of prefrontal cortex lysate showed decreases of Aβ1-40 in both α1/Tg and α2/Tg mice, as compared with Tg mice. Tg versus α1/Tg, *P = 0.0356; Tg versus α2/Tg **P = 0.0226, 1-way ANOVA with Tukey’s post hoc test. F = 5.034. (F) ELISA showed no differences in levels of Aβ1-42 in Tg, α1/Tg, and α2/Tg mice. One-way ANOVA with Tukey’s post hoc test. F = 1.771. (G) The ratio of Aβ42:40 was unaltered in Tg, α1/Tg, and α2/Tg mice. One-way ANOVA with Tukey’s post hoc test. F = 1.635. Tg, n = 12; α1/Tg and α2/Tg, n = 9. (H) Western blot analysis of p-tau (S396 and S262) levels in hippocampus showed no differences among WT, Tg, α1/Tg, and α2/Tg mice. WT, n = 8; Tg, n = 6; α1/Tg, n = 6; α2/Tg, n =7. One-way ANOVA. Box-and-whisker plots represent the interquartile range, with the line across the box indicating the median. Whiskers show the highest and lowest values detected.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts